Signalpoint

← Full daily brief

Business brief

Israeli Corporations Pursue Targeted US Mergers and Acquisitions

Israeli corporate champions Teva, Nayax, and Perion execute strategic acquisitions across biopharma, smart parking, and retail ad networks.

Signalpoint TeamBrief

Business

Nayax's $350 million buyout of IPS Group anchors its cashless payment network across North American infrastructure — establishing a sticky foothold in municipal mobility.

BackgroundNayax provides cashless payment terminals and management software for unattended commerce systems globally. IPS Group operates parking meters, mobile payment applications, and enforcement management across 250,000 parking spaces in North America.

Points
  1. IPS Group expects 2026 revenues to top $90 million, giving Nayax an immediate cash-flowing footprint across North American municipal parking networks.
  2. The buyout expands Nayax's total addressable market by $85 billion, pushing its projected addressable space toward $342 billion by 2029.
  3. Nayax will integrate smart parking meters with its electric vehicle charging payment systems, creating unified municipal mobility platforms for city clients.
SourcesNayax: Nayax Enters into Definitive Agreement to Acquire IPS Group, a Leading Smart Parking Technology Provider (opens in new tab)CTech: Nayax acquiring smart parking company IPS for $350 million (opens in new tab)

Business

Teva is exploiting BioXcel's Chapter 11 filing to scoop up an FDA-stage neuroscience asset at a steep valuation discount — expanding its psychiatry pipeline cheaply.

BackgroundBioXcel filed for Chapter 11 protection after exhausting cash reserves while advancing its central nervous system portfolio. Israeli drugmaker Teva has been pursuing disciplined acquisitions to expand its specialized neuroscience business under its broader growth strategy.

Points
  1. The agreement includes $67.5 million in contingent milestone payments tied directly to commercial target achievements for its agitation drug BXCL501.
  2. BXCL501 faces a critical FDA PDUFA decision date in November 2026 for treating acute agitation in schizophrenia and bipolar disorder patients.
  3. Israeli parent company Teva Pharmaceutical Industries serves as the financial guarantor in Delaware bankruptcy court to back the acquisition agreement.
SourcesGlobeNewswire: Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy (opens in new tab)BioSpace: BioXcel files for bankruptcy, will sell assets to Teva for up to $125M (opens in new tab)

Business

Perion's purchase of PRN bridges digital ad tech with physical store screens — positioning the Israeli adtech firm inside brick-and-mortar retail media.

BackgroundPerion develops digital advertising technologies that connect brand campaigns across web, mobile, and connected television platforms. In-store retail media networks are expanding rapidly as consumer brands seek measurable advertising directly at physical points of sale.

Points
  1. PRN manages exclusive advertising contracts across major warehouse clubs, big-box retail chains, and 2,200 healthcare venues across North America.
  2. Perion projects the acquired business unit, renamed Perion Retail Networks, will generate $3 million in Adjusted EBITDA in 2027.
  3. The transaction links Perion's digital programmatic ad buying engine directly to physical store shelves, offering brands closed-loop attribution for in-person shopping.
SourcesPerion: Perion Acquires PRN, a Leading In-Store Retail Media Company with Exclusive Multi-year Partnerships Across Some of North America's Largest Retailers (opens in new tab)TNW: Perion acquires PRN for up to $12 million, expanding in-store retail media reach across North America (opens in new tab)

Unlock the full brief

Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.

Or read free in the appDownload on the App Store